As further evidenced by this settlement, the DOJ and SEC keep on to signal the dangers connected to ill-described pools of reimbursable distributor bills (e.g. “advertising” or “administration” expenses), the usage of free of charge samples, rebates, as well as other price tag concessions. The Alcon and Novartis AG DPAs undoubtedly are a re